AUROBAC THERAPEUTICS is a biopharmaceutical company founded in 2022 as a joint venture by Boehringer Ingelheim, Evotec, and bioMérieux, aiming to develop the next generation of precision medicines and become leaders in the fight against bacterial infections, antimicrobial resistance, and their consequences such as sepsis in acute hospital settings.

Their pipeline stands out for their commitment to tackling the highest unmet medical needs in the fields of AMR, infectious diseases, and their consequences.

They focus on ESKAPE pathogens, particularly gram-negatives such as Pseudomonas aeruginosa, and on acute hospital settings where there are no satisfactory therapeutic options to date, such as Acute Respiratory Infections (HAP, VAP), Sepsis, and/or Septic Shock. New treatment modalities and classes that can be combined with rapid and actionable diagnostics to follow a precision medicine concept are their priorities.

AUROBAC THERAPEUTICS aims to cover the entire value chain of projects, including research and development, clinical trials, registration, and commercialization.

They focus all our effort on identifying and developing innovative products with the ability to address clear unmet medical needs associated to bacterial infections and increasing AMR, aligned with viable clinical development plans based on a precision medicine concept.

–  Therapeutic areas: AMR, Bacterial Infections, Acute Respiratory Infections, Sepsis & Septic Shock

–  Based in: Lyon (FRANCE)

–  Employees: 11 – 50

–  Created in: 2022